Cargando…

Development and Validation of a Prognostic Nomogram for Extremity Soft Tissue Leiomyosarcoma

Background: Extremity soft tissue leiomyosarcoma (LMS) is a rare disease with a poor prognosis. The aim of this study is to develop nomograms to predict the overall survival (OS) and cancer-specific survival (CSS) of patients with extremity soft tissue LMS. Methods: Based on the Surveillance, Epidem...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, MingFeng, Chen, Gang, Dai, JiaPing, Hu, JunYu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504783/
https://www.ncbi.nlm.nih.gov/pubmed/31119101
http://dx.doi.org/10.3389/fonc.2019.00346
_version_ 1783416634100154368
author Xue, MingFeng
Chen, Gang
Dai, JiaPing
Hu, JunYu
author_facet Xue, MingFeng
Chen, Gang
Dai, JiaPing
Hu, JunYu
author_sort Xue, MingFeng
collection PubMed
description Background: Extremity soft tissue leiomyosarcoma (LMS) is a rare disease with a poor prognosis. The aim of this study is to develop nomograms to predict the overall survival (OS) and cancer-specific survival (CSS) of patients with extremity soft tissue LMS. Methods: Based on the Surveillance, Epidemiology, and End Results (SEER) database, 1,528 cases of extremity soft tissue LMS diagnosed between 1983 and 2015 were included. Cox proportional hazards regression modeling was used to analyze prognosis and obtain independent predictors. The independent predictors were integrated to develop nomograms predicting 5- and 10-year OS and CSS. Nomogram performance was evaluated by a concordance index (C-index) and calibration plots using R software version 3.5.0. Results: Multivariate analysis revealed that age ≥60 years, high tumor grade, distant metastasis, tumor size ≥5 cm, and lack of surgery were significantly associated with decreased OS and CSS. These five predictors were used to construct nomograms for predicting 5- and 10-year OS and CSS. Internal and external calibration plots for the probability of 5- and 10-year OS and CSS showed excellent agreement between nomogram prediction and observed outcomes. The C-index values for internal validation of OS and CSS prediction were 0.776 (95% CI 0.752–0.801) and 0.835 (95% CI 0.810–0.860), respectively, whereas those for external validation were 0.748 (95% CI 0.721–0.775) and 0.814 (95% CI 0.785–0.843), respectively. Conclusions: The proposed nomogram is a reliable and robust tool for accurate prognostic prediction in patients with extremity soft tissue LMS.
format Online
Article
Text
id pubmed-6504783
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-65047832019-05-22 Development and Validation of a Prognostic Nomogram for Extremity Soft Tissue Leiomyosarcoma Xue, MingFeng Chen, Gang Dai, JiaPing Hu, JunYu Front Oncol Oncology Background: Extremity soft tissue leiomyosarcoma (LMS) is a rare disease with a poor prognosis. The aim of this study is to develop nomograms to predict the overall survival (OS) and cancer-specific survival (CSS) of patients with extremity soft tissue LMS. Methods: Based on the Surveillance, Epidemiology, and End Results (SEER) database, 1,528 cases of extremity soft tissue LMS diagnosed between 1983 and 2015 were included. Cox proportional hazards regression modeling was used to analyze prognosis and obtain independent predictors. The independent predictors were integrated to develop nomograms predicting 5- and 10-year OS and CSS. Nomogram performance was evaluated by a concordance index (C-index) and calibration plots using R software version 3.5.0. Results: Multivariate analysis revealed that age ≥60 years, high tumor grade, distant metastasis, tumor size ≥5 cm, and lack of surgery were significantly associated with decreased OS and CSS. These five predictors were used to construct nomograms for predicting 5- and 10-year OS and CSS. Internal and external calibration plots for the probability of 5- and 10-year OS and CSS showed excellent agreement between nomogram prediction and observed outcomes. The C-index values for internal validation of OS and CSS prediction were 0.776 (95% CI 0.752–0.801) and 0.835 (95% CI 0.810–0.860), respectively, whereas those for external validation were 0.748 (95% CI 0.721–0.775) and 0.814 (95% CI 0.785–0.843), respectively. Conclusions: The proposed nomogram is a reliable and robust tool for accurate prognostic prediction in patients with extremity soft tissue LMS. Frontiers Media S.A. 2019-05-01 /pmc/articles/PMC6504783/ /pubmed/31119101 http://dx.doi.org/10.3389/fonc.2019.00346 Text en Copyright © 2019 Xue, Chen, Dai and Hu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xue, MingFeng
Chen, Gang
Dai, JiaPing
Hu, JunYu
Development and Validation of a Prognostic Nomogram for Extremity Soft Tissue Leiomyosarcoma
title Development and Validation of a Prognostic Nomogram for Extremity Soft Tissue Leiomyosarcoma
title_full Development and Validation of a Prognostic Nomogram for Extremity Soft Tissue Leiomyosarcoma
title_fullStr Development and Validation of a Prognostic Nomogram for Extremity Soft Tissue Leiomyosarcoma
title_full_unstemmed Development and Validation of a Prognostic Nomogram for Extremity Soft Tissue Leiomyosarcoma
title_short Development and Validation of a Prognostic Nomogram for Extremity Soft Tissue Leiomyosarcoma
title_sort development and validation of a prognostic nomogram for extremity soft tissue leiomyosarcoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6504783/
https://www.ncbi.nlm.nih.gov/pubmed/31119101
http://dx.doi.org/10.3389/fonc.2019.00346
work_keys_str_mv AT xuemingfeng developmentandvalidationofaprognosticnomogramforextremitysofttissueleiomyosarcoma
AT chengang developmentandvalidationofaprognosticnomogramforextremitysofttissueleiomyosarcoma
AT daijiaping developmentandvalidationofaprognosticnomogramforextremitysofttissueleiomyosarcoma
AT hujunyu developmentandvalidationofaprognosticnomogramforextremitysofttissueleiomyosarcoma